---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-26-000072"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2026-08-26T10:38:55+00:00"
generated_at: "2026-08-26T10:40:12.585524+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Biohaven licenses opakalim/Kv7 platform to SK Biopharmaceuticals for up to $795M

## Summary
- SK Biopharmaceuticals licenses Biohaven's Kv7 platform led by opakalim, a Phase 2/3 selective Kv7.2/7.3 activator for focal epilepsy.
- Biohaven receives $400M upfront ($350M at close, $50M in 2027) plus up to $150M development and regulatory milestones.
- Tiered royalties on U.S. opakalim net sales range from mid-teens to low twenties; mid-single-digit on ex-U.S. net sales.
- SKBP assumes up to $245M Knopp obligations: $185M on U.S./EMA approval of opakalim and up to $60M for future Kv7 programs.
- Closing subject to antitrust clearance (HSR); RISE3 topline results expected in 2H 2026.

## SEC filing metadata
- accession: 0001935979-26-000072
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2026-08-26T10:38:55+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597926000072/0001935979-26-000072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597926000072/bhvn-20260826.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-26-000072
- JSON: https://secwatch.observer/filing/0001935979-26-000072.json
- Plain text: https://secwatch.observer/filing/0001935979-26-000072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.